Introduction Testicular sperm extraction (TESE) is a widely used clinical method for recovering spermatozoa in patients with azoospermia. However, the prediction of sperm retrieval outcomes with TESE is challenging due to absence of clinically proven bio-markers. Anti-Müllerian hormone (AMH) is a homodimeric glycoprotein, a member of the transforming growth factor-β superfamily. AMH acts as an extremely sensitive marker of ovarian aging and a valuable tool in the diagnosis and the recognition of azoospermia.
This week’s Journal Watch summarizes the trial “ Contribution of serum anti-Müllerian hormone in the management of azoospermia and the prediction of testicular sperm retrieval outcomes, ” published in BMC Journal of Basic and Clinical Andrology . 1 Authors: Hamza Benderradji, Julie Prasivoravong, François Marcelli, et al. What was the need for this study? According to a WHO…
